Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer - Reply

被引：1
|
作者：
Sabbatini, Paul
Odunsi, Kunle
机构：
[1] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol Serv, New York, NY 10021 USA
[2] Roswell Pk Canc Inst, Div Gynecol Oncol, Buffalo, NY 14263 USA
来源：
CLINICAL CANCER RESEARCH | 2007年 / 13卷 / 13期
关键词：
D O I：
10.1158/1078-0432.CCR-07-0718
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4026 / 4027
页数：2
相关论文
共 50 条
  • [41] Phase I trial of the anti-idiotypic monoclonal antibody (mAb) ACA-125 in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Sabbatini, P
    Aghajanian, C
    Dupont, J
    Derosa, F
    Anderson, S
    McGuire, W
    Rodabaugh, K
    Ferrone, S
    Lele, S
    Odunsi, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 453S - 453S
  • [42] Safety and Outcome of Patients Treated with a Modified Outpatient Intraperitoneal Regimen for Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
    Battelli, Chiara
    Campo, Meghan
    Buss, Mary K.
    Awtrey, Christopher S.
    Konstantinopoulos, Panagiotis A.
    CHEMOTHERAPY, 2013, 59 (04) : 251 - 259
  • [43] Phase I study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Slomovitz, B. M.
    Coleman, R. L.
    Levenback, C.
    Jung, M.
    Gershenson, D. M.
    Wolf, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 278S - 278S
  • [44] SECOND PRIMARY CANCER AFTER PRIMARY PERITONEAL, EPITHELIAL OVARIAN, FALLOPIAN TUBAL CANCER
    Lim, M. C.
    Lim, J.
    Salehi, T.
    Young-Joo, L.
    Yoo, C. W.
    Bristow, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 754 - 754
  • [45] Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy
    Liu, Marisa C.
    Sutedja, Joyce
    Tewari, Krishnansu S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (05) : 475 - 480
  • [46] New FIGO classification of ovarian, fallopian tube and primary peritoneal cancer
    Hoehn, A. K.
    Einenkel, J.
    Wittekind, C.
    Horn, L. -C.
    PATHOLOGE, 2014, 35 (04): : 322 - 326
  • [47] Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
    Ursula Matulonis
    Suzanne Berlin
    Hang Lee
    Christin Whalen
    Elizabeth Obermayer
    Richard Penson
    Joyce Liu
    Susana Campos
    Carolyn Krasner
    Neil Horowitz
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 417 - 423
  • [48] Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
    Matulonis, Ursula
    Berlin, Suzanne
    Lee, Hang
    Whalen, Christin
    Obermayer, Elizabeth
    Penson, Richard
    Liu, Joyce
    Campos, Susana
    Krasner, Carolyn
    Horowitz, Neil
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (02) : 417 - 423
  • [49] A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
    Cristea, Mihaela C.
    Stewart, Daphne
    Synold, Timothy
    Ruel, Nora
    Mortimer, Joanne
    Wang, Edward
    Jung, Alexander
    Wilczynski, Sharon
    Konecny, Gottfried E.
    Eng, Melissa
    Kilpatrick, Lindsay
    Han, Ernest
    Dellinger, Thanh
    Hakim, Amy
    Lee, Stephen
    Morgan, Robert J.
    Wakabayashi, Mark T.
    Frankel, Paul H.
    GYNECOLOGIC ONCOLOGY, 2024, 182 : 124 - 131
  • [50] Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer
    Taylor, Sarah E.
    Chu, Tianjiao
    Elvin, Julia A.
    Edwards, Robert P.
    Zorn, Kristin K.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 32 - 37
12345